Cingulate (CING) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cingulate (CING) has outperformed PMV Pharmaceuticals (PMVP) over the past year, gaining 27.8% versus a loss of 33.6%. Cingulate is the larger company by market cap ($67.5 million vs $66.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | PMVP |
|---|---|---|
| Share price | $4.51 | $0.876 |
| Market cap | $67.48M | $66.17M |
| 1-day change | -14.26% | -33.13% |
| YTD return | +3.92% | -29.92% |
| 1-year return | +27.76% | -33.64% |
| 5-year return | — | -96.22% |
| EPS (TTM) | $-2.67 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-22.45M | $-77.74M |
| 52-week high | $11.89 | $1.91 |
| 52-week low | $3.16 | $0.66 |
| Distance from 52-week high | -62.07% | -54.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +370.07% | +356.62% |
| Average volume | 178.82K | 787.50K |
| Shares outstanding | 14.96M | 75.53M |
| Employees | 14 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed PMVP by 61.4 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
CING vs PMVP FAQ
Which is bigger, Cingulate or PMV Pharmaceuticals?
Cingulate (CING) is larger, with a market capitalization of $67.48M compared with $66.17M for PMV Pharmaceuticals (PMVP).
Which stock has performed better over the past year, CING or PMVP?
CING returned +27.76% over the past 12 months, compared with -33.64% for PMVP (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.